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Background: Mapping patient and work flow and cost analysis studies can help determine the most efficient and
cost effective way of providing health services while still maintaining the best standards of care. This study used
both time and motion methodology and hospital data to assess the contribution of staff time and facility usage to
the overall cost of cancer care during patient visits to a comprehensive cancer centre in Quebec, using metastatic
colorectal cancer as a model.
Methods: A workflow diagram was created mapping direct and indirect steps involved during a patient’s physician
or treatment (FOLFOX/bevacizumab or XELOX/bevacizumab) visit. Staff were timed as they performed each task
and this data together with compensation amounts were used to calculate personnel costs. Mean work times and
95% confidence intervals (CI) were calculated. Operation and maintenance (O&M) costs for the Centre were
calculated using information from hospital databases. All costs were presented in constant Canadian dollars for the
2010–2011 fiscal year period.
Results: For physician visits, direct and indirect personnel costs were $9.25 (95%CI:$7.00-$11.51) and O&M costs
were $60.21, for a total of $69.46 (95%CI:$67.21-$71.72). For treatment visits, personnel and O&M costs were $71.91
(95%CI:$45.53-$98.29) and $62.00 respectively for a total of $133.91 (95%CI:$107.53-$160.29). When calculated for
treatment alone, the total cost was $136.06 (95%CI:$109.16-$162.95) for FOLFOX/bevacizumab and $119.94 (95%CI:
$96.89-$142.99) for XELOX/bevacizumab. The highest cumulative personnel costs were for the pharmacists and
nurses ($38.87 and $34.82 respectively). Regarding patient flow, total time in between steps was 77.6 and 49.5
minutes for a physician or treatment visit respectively.
Conclusions: This study from a health care provider’s perspective, demonstrated that in the context of increasingly
expensive therapies, costs associated with staff time and facility usage do not contribute greatly to the overall cost
of treating cancer at this cancer centre. It also illustrated the need for improvements in patient and work flow to
reduce wait times in the clinic.
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With the increased use of health care services due to the
aging population as well as population growth, and the
ballooning health care costs, it has become apparent that
changes need to be made to increase efficiency and re-
duce costs while maintaining optimal standards of care.
In Canada, the number of new cancer cases is expected
to increase 75% in 25 years from 160,000 in 2006 to
280,000 in 2031 [1]. It has been estimated that the an-
nual cost for providing treatment and services to cancer
patients in Canada is approximately $5 billion (1). These
challenges are not unique to Canada. Institutions around
the world are performing cost analysis studies to deter-
mine the breakdown of costs for treating particular can-
cers, or to compare the cost effectiveness of different
treatment regimens, in order to assess the financial bur-
den on their health care system [2-8].
Time and motion studies have long been used to as-
sess work processes. In health care delivery, such
studies are performed, notably to modify existing proce-
dures, implement new ones, improve efficiency and re-
duce costs. In the early 1990’s, a time and motion study
was conducted to evaluate the efficiency of multileaf
collimators (MLC) in the delivery of radiotherapy [9].
Another study which compared three types of surgical
sessions in a dermatology clinic identified not only the
most efficient method, but also which work steps were
causing delays in the provision of service [10]. A time
and motion study was also implemented to look at the
time spent on various tasks by medical-surgical nurses
to identify ways of improving nursing care [11]. Time
and motion studies can also be used to measure the
overall cost of performing routine screening proce-
dures such as a colonoscopy [12] as well as the
utilization of resources and time involved in treating
co morbidities of chronic diseases such as cancer [13].
In the oncology clinic this methodology has been used
to determine the time and cost of administering cer-
tain treatments to cancer patients [14], and to com-
pare the overall cost of two different cancer treatments
[15]. In a hematology-oncology inpatient unit a time
and motion study was implemented to assess daily
workload of nurses [16].
The Segal Cancer Centre located at the Jewish Gen-
eral Hospital in Montreal was opened in 2006 to meet
the growing need for a state of the art comprehensive
cancer facility within the hospital to replace the previ-
ous small and over-crowded oncology clinic. The hos-
pital is affiliated with McGill University and services
patients from across the province of Quebec. In ac-
cordance with Canadian trends, the Centre has seen a
dramatic increase in the number of patients resulting
in increased costs to the health care system and space
constraints during busy clinic times.The purpose of this study was to assess from a health
care provider’s perspective, the contribution of staff
time and facility usage to the cost of treating patients
at the Segal Cancer Centre using metastatic colorectal
cancer as a model, with the treatment regimens being
either FOLFOX (Folinic Acid, Fluorouracil, Oxaliplatin)/
bevacizumab or XELOX (Capecitabine, Oxaliplatin)/
bevacizumab. The question is whether these costs add
considerably to drug costs, or are the cost of the drugs
themselves the most significant challenge to the health
care system. A secondary goal was to map patient and
work flow during a patient’s physician and treatment
visit to assess efficiency. For this purpose, a ‘real-time’
analysis based on time and motion methodology was
performed.
Colorectal cancer is ideal as a model for this study be-
cause it is the third most common cancer in Canada,
affecting both men and women [17]. In the past, median
survival for metastatic colorectal cancer was measured
in months, but more recently we and others have
reported extension of life beyond three years [18,19].
Since as many as 40% of all colorectal cancer patients
will at some point metastasize, this represents an im-
portant point in the disease trajectory from a health re-
source viewpoint. Furthermore, because survival with
metastatic colorectal cancer is progressively improving,
including a small number of patients who might have
very long term disease-free survival as a result of surgi-
cal resection of metastases, this represents an increas-
ingly important patient group.
While cost analysis studies have been done to deter-
mine the medical costs of treating cancer from a health
care provider’s or payer’s perspective, to our knowledge,
this is the first study that uses a combination of time
and motion methodology for mapping patient and work
flow and assessing staff time, and hospital data for deter-
mining facility usage, to ascertain their specific contribu-
tions to the overall costs of treating cancer.
Methods
Time and motion study
Following discussions with a number of health care pro-
viders and administrative staff, a workflow diagram was
created to map the direct and indirect work steps and
type of personnel involved during physician or treatment
visits (Figure 1). Signed consent forms were obtained
from all staff and patients who participated in the study.
A research assistant (RA) was hired to serve as the time-
keeper. Eligible patients were those with metastatic colo-
rectal cancer age 18 years or older undergoing treatment
with FOLFOX/bevacizumab or XELOX/bevacizumab.
The RA followed the patient from step to step during the
duration of the visit and used a stopwatch to record the
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Figure 1 Workflow Diagram – Physician and Treatment Visits.
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ation step timing began from the moment the patient
entered the examination room, even if the physician did
not immediately enter.
Figure 1 shows the nine steps where staff directly
interacted with the patient during the physician or treat-
ment visit (green boxes). On occasion a patient would
speak to a dietitian, social worker or physiotherapist dur-
ing either visit (Other Steps, orange box) and this inter-
action was timed if the RA was present. During the
treatment step, at various times the nurse administeredthe different drugs involved in the treatment regimen
(premedication, 5-fluorouracil, leucovorin, oxaliplatin,
bevacizumab, calcium/magnesium), talked to the patient
or checked the drug infusion pump. To afford the pa-
tient and family as much privacy as possible, the RA did
not remain with the patient during the entire course of
treatment. Instead, she timed the work steps involved
in starting the treatment, then returned to time each
medication changeover, and then the discharge step. The
duration of time the nurse spent with the patient during
the treatment step was determined by adding up the
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the length of time required to disconnect the pump and
measure vital signs, as well as any other interactions
with the nurse or other staff prior to the patient leaving
the premises. Direct steps that took under 1 minute to
perform were rounded up to 1 minute. For steps taking
longer than 1 minute, anything equal to or above the 10
second mark was rounded up to the nearest minute and
anything below was rounded down.
There were twelve indirect steps (Figure 1, lavender
boxes) performed in preparation for, or as a result of,
the direct steps, and four possible post-treatment steps
(Figure 1, Other Steps, blue boxes) as required. The
times for the post-treatment steps were mainly deter-
mined by chart review or from the staff person involved.
Since this study did not involve more than minimal
risk (in accordance with article 1.6 of the Canadian Tri-
Council Policy Statement of Ethical Conduct for Re-
search Involving Humans), the Jewish General Hospital’s
Research Ethics Office granted expedited approval as
protocol #09-129, with corroborative approval of the Re-
search Ethics Committee.
Cost analysis
For the time and motion portion, four statistics are
reported: the number of timed observations, the mean
duration of each timed step, and the 95% confidence
intervals (CI) around the mean duration, calculated
using a two-sided t-Student distribution. Time results
are reported in minutes both for the visit duration and
total worked time (i.e. all minutes worked by all
employees, or person-minutes) during each visit step.
The cost analysis component of the study involved the
collection of information about the Centre’s costs for
the fiscal year April 1, 2010-March 31, 2011, from the
hospital databases. All costs are presented in constant
Canadian dollars during this 2010–2011 time period.
The unit cost of a visit consists of personnel costs and
operation and maintenance (O&M) costs. Personnel
costs represent the cost of work performed by Segal
Cancer Centre staff during the direct and indirect work
steps and were obtained by multiplying the mean dur-
ation of each work step by the total hourly rate (includ-
ing benefits) of the specific personnel category involved
in the task. O&M costs consist of equipment (in the
exam rooms, treatment area, pharmacy and laboratory)
and other operational costs (sterilization, laundry/dry
cleaning, biomedical waste management, operational fa-
cilities, security, maintenance and repair, mail, telecom-
munications). Equipment costs were calculated based
on the estimated acquisition costs in 2010–2011 of
existing Segal Cancer Centre equipment (exam tables,
diagnostic kits, digital thermometers, recliners, treat-
ment beds, IV pumps, crash cart, automatic NIBP,computerized narcotic dispensing machine, digital scale,
nurse call system, pharmacy hoods, refrigerators and
freezers), their expected useful life span, and the num-
ber of equipment items purchased each year. Other
O&M costs were drawn from the overall hospital costs,
and attributed to the Segal Cancer Centre based on (a)
the share of patient visits to the Segal Cancer Centre
(sterilization, laundry/dry cleaning, biomedical waste
management) or (b) the floor area of the Segal Cancer
Centre relative to the entire hospital (operational facil-
ities, security, maintenance and repair, mail, telecom-
munications). Total O&M costs per visit were obtained
by dividing total costs attributable to the Segal Cancer
Centre by the total number of patient visits at the
Centre.
Since physician salaries and pharmaceutical costs are
covered by Quebec’s public health care plan (“Régie de
l’assurance-maladie du Québec”) rather than by budgets
of the Segal Cancer Centre or of the Jewish General Hos-
pital, these costs are classified as “medical” and, as such,
were excluded from our cost calculations. However, to
provide an overall picture of economic costs, the Discus-
sion section compares the costs of the contribution of
staff time and facility usage, which are our main focus,
with physician salaries and pharmaceutical costs.
All analyses were conducted using MicrosoftW Office
Excel 2003 (Microsoft Corporation, Redmond, WA).
Statistical significance is defined as a two-sided α-level
of 0.05 or less.
Results
Twenty-four patients (14 female, 10 male) with a mean
age of 63 (41–85) were followed. There were a total of
48 physician visits (36 physician only and 12 physician/
treatment) and 60 treatment visits (48 treatment only
and 12 physician/treatment). Of the treatment visits, 52
(86.7%) were FOLFOX/bevacizumab and 8 (13.3%) were
XELOX/bevacizumab.
Table 1 shows the mean time of each direct work step
and the mean time worked by the employee for both the
physician and treatment visits. For some work steps
there were fewer observations (n) due to missed timings
for a variety of reasons. The average total duration of
the physician visit was 129.2 (95%CI:114.2-144.2) min-
utes, whereas the mean duration of the timed work steps
was 51.6 (95%CI:46.3-57.1) minutes. For treatment visits,
the average total duration was 393.0 (95%CI:374.9–
411.1) minutes, with timed work steps taking up 343.5
(95%CI:328.1–358.7) minutes. Therefore, waiting or in-
transit times were 77.6 minutes during physician visits
(60% of visit time), and 49.5 minutes during treatment
visits (13% of visit time).
Registration for physician or treatment visits, weighing
and checking in at pharmacy were quick steps, i.e. 1–2
Table 1 Direct Work Steps: Average duration of each step and time worked by employee
Direct Work Steps n Mean Time (min)
(95% Confidence Interval)
Physician Visits
Average Total Duration of Physician Visit 48 129.2 (114.2 – 144.2)
7th floor registration (secretary) a, b 45 1.3 (1.1 - 1.6)
Blood Test – Physician Visit (phlebotomist or nurse) a,b 36 3.6 (2.7 - 4.5)
1. phlebotomist* 27 2.7 (2.0 - 3.4)
2. nurse* 9 6.2 (3.4 - 9.0)
Weighing (orderly) a, b 42 1.0 (0.9 - 1.1)
Appointment with Oncologist (physician) a 48 33.3 (28.4 - 38.2)
Appointment Booking (secretary) a, b 44 12.1 (10.1 - 14.1)
Other - Physician Visit (secretary, nurse, physiotherapist) a, b 48 0.3 (−0.1 - 0.7)
Total mean duration of timed visit steps a 51.6 (46.3 - 57.1)
Total mean time worked by employees (excluding physicians)b 18.3 (14.1 – 22.6)
Treatment Visits
Average Total Duration of Treatment Visit 60 393.0 (374.9 – 411.1)
8th floor registration (secretary) c, d 36 1.1 (1.0 - 1.2)
Blood Test – Treatment Visit (phlebotomist or nurse) c, d 35 9.9 (6.8 - 13.0)
1. phlebotomist* 12 2.9 (2.1 - 3.7)
2. nurse* 23 13.5 (9.3 - 17.7)
Pharmacy (secretary) c, d 47 1.4 (1.1 - 1.6)
Treatment (overall treatment time) c 60 322.7 (308.1 - 337.4)
Treatment (nurse time) d 60 24.6 (18.2 - 31.0)
Oncologist consultation during treatment visit c 48 0.5 (0.0 - 0.9)
Discharge (overall discharge time) c 58 6.3 (3.3 - 9.3)
Discharge (nurse time) d 58 11.0 (−1.0 - 23.1)
Other- Treatment Visit (dietitian, social worker) c, d 60 1.6 (0.5 - 2.8)
Total mean duration of timed visit steps c 343.5 (328.1 - 358.7)
Total mean time worked by employees d 49.6 (26.1 – 73.1)
Other Visits (determined by chart review)
Unscheduled visits to clinic 10 121.8
Phone calls (nurse) 3 20.0
Cancer Nutrition-Rehabilitation Program 3 139.0
Emergency Room visits 11 794.8
aApplicable for duration of work step.
bApplicable for time worked by employee.
cApplicable for duration of work step.
dApplicable for time worked by employee.
*Whether blood is taken by the nurse or phlebotomist is dependent on the special circumstances of the patient, therefore when calculating the total mean time
worked by employees the combined mean time was used rather than the individual mean times for the phlebotomist and the nurse.
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CI:2.7–4.5) and 9.9 (95%CI:6.8–13.0) minutes for the
physician and treatment visits respectively, and was
either done by a nurse or a phlebotomist, depending on
whether or not the patient had a portacath for vascular
access. The appointment-booking time, 12.1 (95%
CI:10.1–14.1) minutes, is fairly long due to the lengthy
procedures required to contact other clinics and bookscans and other procedures for the patient. The mean
time for the consultation with the oncologist was 33.3
(95%CI:28.4–38.2) minutes. Thus for hospital staff only,
the mean time worked per physician visit was 18.3 (95%
CI:14.1-22.6) minutes.
The average nurse time with the patient during treat-
ment was 24.6 (95%CI:18.2–31.0) minutes out of the
total treatment duration of 322.7 (95%CI:308.1–337.4)
Table 2 Indirect Work Steps: Average duration of each step and time worked by employee
Indirect Work Steps n Mean Time (min)
(95% Confidence Interval)
Physician Visits
Exam room preparation and cleanup (orderly) 27 1.1 (1.0 - 1.2)
Sending tubes of blood down to laboratory (phlebotomist) 10 1.0 (0.8 - 1.2)
Retrieving and filing patient charts (clerk) 300 0.6 (0.6 - 0.7)
Total mean time worked by employees 2.7 (2.3 - 3.1)
Treatment Visits
FOLFOX (n=52); XELOX (n=8)
Sending tubes of blood down to laboratory (phlebotomist) a, b 10 1.0 (0.8 - 1.2)
Retrieving and filing patient charts (clerk) a, b 300 0.6 (0.6 - 0.7)
Prescription validation (pharmacist) a, b 16 5.3 (4.0 - 6.5)
Preparation of calcium and magnesium a, b 44 6.5 (6.0 - 6.8)
1. pharmacist 44 2.8 (2.8 - 2.8)
2. pharmacy technician 44 3.7 (3.3 - 4.0)
Preparation of FOLFOX (5-FU, leucovorin, oxaliplatin) a 6 39.6 (35.9 - 43.3)
1. pharmacist 6 18.6 (14.5 - 22.7)
2. pharmacy technician 6 21.0 (16.7 - 25.2)
Pre-counts of capecitabine and labeling (pharmacy technician) b 10 2.0 (2.0 - 2.0)
Preparation of capecitabine tablets for XELOX treatment b 6 3.4 (2.3 - 4.5)
1. pharmacist 6 0.5 (0.2 - 0.8)
2. pharmacy technician 6 2.9 (2.1 - 3.7)
Preparation of oxaliplatin for XELOX treatment b 9 7.9 (7.2 - 8.5)
1. pharmacist 9 3.9 (3.4 - 4.4)
2. pharmacy technician 9 4.0 (3.5 - 4.4)
Preparation of bevacizumab a, b 6 10.1 (8.4 - 11.8)
1. pharmacist 6 4.9 (3.8 - 6.0)
2. pharmacy technician 6 5.2 (3.6 - 6.9)
Prescription/treatment verification (nurse) a, b 14 4.5 (−0.8 - 9.8)
Preparation and verification of IV bags, premeds (nurse) a, b 54 2.4 (1.9 - 3.0)
Total mean time worked by employees (all indirect steps)
(Based on 86.7% FOLFOX/bevacizumab – n=52; 13.3% XELOX/bevacizumab – n=8)
66.5 (59.6 - 73.2)
Total mean time worked by employees
1. FOLFOX/bevacizumab treatment a 70.0 (67.1 - 72.7)
2. XELOX/bevacizumab treatment b 43.7 (41.2 - 46.0)
aApplicable to FOLFOX/bevacizumab treatment.
bApplicable to XELOX/bevacizumab treatment.
Shinder et al. BMC Health Services Research 2012, 12:370 Page 6 of 10
http://www.biomedcentral.com/1472-6963/12/370minutes. Overall discharge time was 6.3 (95%CI:3.3–
9.3) minutes, however the nurse time was 11.0 (95%
CI:-1.0–23.1) minutes because in some cases there were
complications during discharge which required the
presence of more than one nurse. The average time
worked by employees during the treatment visit was
49.6 (95%CI:26.1–73.1) minutes. While dietitians, social
workers and physiotherapists are sometimes required
by patients, in our particular study this was not a fre-
quent occurrence.Complications following treatment often result in un-
scheduled patient visits to the clinic, emergency room
visits, phone calls to the nurse, and/or appointments at
the Cancer Nutrition-Rehabilitation Program clinic.
Since these steps were not timed by the RA and there
was limited information, they were not included in the
cost analysis.
Table 2 shows the mean time worked by employees for
each of the indirect steps, which amounted to totals of 2.7
(95%CI:2.3–3.1) and 66.5 (95%CI:59.6–73.2) minutes for




Personnel Costs $9.25 ($7.00 - $11.51)
1. Direct work steps $8.08 ($6.00 - $10.16)
2. Indirect work steps $1.17 ($1.00 - $1.35)
Operation and Maintenance (O&M)
Costs
$60.21 (NA)
1. O&M cost excluding equipment $22.44 (NA)
2. Specific equipment costs $37.77 (NA)
Total cost for physician visit $69.46 ($67.21 - $71.72)
Treatment Visits
Personnel Costs $71.91 ($45.53 – $98.29)
1. Direct work steps a, b $31.80 ($16.53 - $47.07)
2. Indirect work steps $40.11 ($28.99 – $51.22)
3. FOLFOX/bevacizumab a $42.26 ($30.63 - $53.88)
4. XELOX/bevacizumab b $26.14 ($18.36 - $33.93)
Operation and Maintenance Costs a, b $62.00 (NA)
1. O&M cost excluding equipment $22.44 (NA)
2. Specific equipment costs $39.56 (NA)
Total cost for treatment visit $133.91 ($107.53 – $160.29)
1. FOLFOX/bevacizumaba $136.06 ($109.16 - $162.95)
2. XELOX/bevacizumab $119.94 ($96.89 - $142.99)
aApplicable to FOLFOX/bevacizumab treatment.
bApplicable to XELOX/bevacizumab treatment.
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visits, employee time was longer for patients treated with
FOLFOX/bevacizumab, 70.0 (95%CI:67.1–72.7) minutes,
than with XELOX/bevacizumab, 43.7 (95%CI:41.2–46.0)
minutes. The actual preparation of FOLFOX took 39.6
(95%CI:35.9-43.3) minutes of employee time, whereas the
preparation of XELOX took a total of 13.3 minutes (cape-
citabine pre-counts: 2.0 (95%CI:2.0-2.0) minutes; capecita-
bine preparation: 3.4 (95%CI:2.3-4.5) minutes, oxaliplatin
preparation: 7.9 (95%CI:7.2-8.5) minutes).
Table 3 shows the personnel (direct and indirect steps)
and O&M costs per patient visit. For the physician visit,
they were $9.25 (95%CI:$7.00-$11.51) and $60.21 re-
spectively, for a total of $69.46 (95%CI:$67.21-$71.72).
For the treatment visit they were $71.91 (95% CI:$45.53-
$98.29) and $62.00 respectively, for a total of $133.91
(95%CI:$107.53-$160.29). The total costs per treatment
visit for FOLFOX/bevacizumab and XELOX/bevacizu-
mab were $136.06 (95%CI:$109.16-$162.95) and $119.94
(95%CI:$96.89-$142.99) respectively.
Table 4 shows the breakdown of mean time worked by
employee category and their respective personnel costs.
For pharmacy, although the cumulative mean time
worked was similar for the technician and pharmacist(47.7 and 48.8 minutes respectively), the personnel cost
for the pharmacist was higher ($38.87 versus $18.95).
The total pharmacy staff time for the preparation of
FOLFOX/bevacizumab was longer than for XELOX/
bevacizumab (61.4 versus 35.1 minutes) and is more
expensive with respect to personnel costs ($36.97 ver-
sus $20.85). Regarding nursing, the treatment step was
the most time consuming (24.6 minutes) and therefore
the most costly ($16.18 out of a total cost of $34.82). For
secretarial staff, appointment booking was the most time
consuming (12.1 minutes) and costly ($4.86) step. The
combined personnel costs for the phlebotomist, orderly,
clerk and other were just over $5.00. Thus, of all the staff
involved, it was pharmacist and nurse time which
resulted in the highest personnel costs.
Discussion
Patients treated at the Segal Cancer Centre proceed
through a standard route when they arrive for an ap-
pointment with their oncologist or for receipt of their
treatment. In this study we mapped out that route,
determined the length of time staff spend attending to
the patient at each step and what that translates into
with regards to personnel costs. We also assessed the
cost of usage of the oncology clinic and treatment area
which encompasses two floors of one pavilion in the
hospital.
Cost analysis studies from different countries compar-
ing XELOX and FOLFOX have routinely shown the
former to be less expensive when taking into account
the cost of purchasing and administering the drugs, the
management of serious adverse events and other medical
resource utilization costs [5-8]. In contrast, our study fo-
cused on the contribution of staff time and facility usage
to the cost per patient visit and demonstrated that it was
only approximately 12% lower with XELOX. Thus it
appears that the self-administered oral medication, capeci-
tabine, has no significant financial advantage with regards
to staff time and facility usage because of the preparation
and administration of drugs requiring intravenous access
and infusion (oxaliplatin and bevacizumab).
The 2011 drug costs of FOLFOX/bevacizumab (modi-
fied FOLFOX6, bevacizumab, calcium and magnesium)
and XELOX/bevacizumab (capecitabine, bevacizumab,
oxaliplatin, calcium and magnesium) were $3,324/cycle
given every two weeks and $5,603/cycle given every
three weeks, respectively. The physician fee per follow-
up visit, which usually occurs every second treatment,
was $41.90. Taking into account the personnel and
O&M costs determined here for each treatment
($136.06/cycle and $119.94/cycle respectively), in a 12-
week time span the cost per patient of administering the
treatment is $20,886 for FOLFOX/bevacizumab and
$22,976 for XELOX/bevacizumab.
Table 4 Breakdown of mean time worked and costs by personnel (C$)
Category Mean Time Worked Cost Portion of Cost Portion of Cost
(min) Physician Visit Treatment Visit
1. Pharmacy
a. Technician
i. Preparation of FOLFOX/bevacizumab 29.9 $11.88 $11.88
ii. Preparation of XELOX/bevacizumab 17.8 $7.07 $7.07
b. Pharmacist
i. Preparation of FOLFOX/bevacizumab 31.5 $25.09 $25.09
ii. Preparation of XELOX/bevacizumab 17.3 $13.78 $13.78
Total pharmacy for FOLFOX/bevacizumab (n=52) 61.4 $36.97 $36.97
Total pharmacy for XELOX/bevacizumab (n=8) 35.1 $20.85 $20.85
Treatment Average (86.7% FOLFOX; 13.3% XELOX) $34.81 $34.81
2. Nursing
a. Blood (physician and treatment visits)* 10.4 $6.84 $1.02 $5.82
b. Treatment 24.6 $16.18 $16.18
c. Discharge 11.0 $7.25 $7.25
d. Prescription verification 4.5 $2.94 $2.94
e. Preparation of IV bags 2.4 $1.61 $1.61
Total 52.9 $34.82 $1.02 $33.80
3. Phlebotomist
a. Blood (physician and treatment visits)* 3.0 $1.61 $1.08 $0.53
b. Sending tubes of blood down to laboratory (physician and treatment visits) 2.0 $1.04 $0.52 $0.52
Total 5.0 $2.65 $1.60 $1.05
4. Secretary
a. 7th floor registration 1.3 $0.53 $0.53
b. Appointment booking 12.1 $4.86 $4.86
c. 8th floor registration 1.1 $0.43 $0.43
d. Pharmacy secretary 1.4 $0.55 $0.55
Total 15.9 $6.37 $5.39 $0.98
5. Orderly
a. Weighing 1.0 $0.38 $0.38
b. Exam room preparation 1.1 $0.43 $0.43
Total 2.1 $0.81 $0.81
6. Clerk
Retrieving and filing patient charts (physician and treatment visits) 1.2 $0.46 $0.23 $0.23
7. Other
(physician and treatment visits) 2.0 $1.24 $0.20 $1.04
TOTAL $81.16 $9.25 $71.91
*Whether blood is taken by the nurse or phlebotomist is dependent on the special circumstances of the patient, therefore the mean time worked was calculated
using n= combined number of observations for the nurse and for the phlebotomist.
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stration that for the treatment of metastatic colorectal
cancer, personnel and O&M costs are minimal, with
drug costs contributing >95% of the total cost. This find-
ing holds true across the entire calculated confidence
intervals, which reflect the sensitivity of time results.Indeed, because all costs in the model were based on
mean values of collected data on actual time rather than
deterministic fixed parameters, the uncertainty in the
model is captured through confidence intervals rather
than sensitivity analyses. Given that the patient flow and
work steps are similar across cancer types at the Segal
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cancers with some minor variations depending on the
cancer type and the cost of treatments.
There were several limitations to this study. Indirect
steps were determined separately from the direct steps
and therefore were not linked to a particular patient visit.
Furthermore, some indirect steps were performed in
batches (e.g. blood samples sent to laboratory, preparation
of calcium/magnesium) rather than individually for each
patient visit. Although every effort was made to time all
direct work steps of each patient visit, due to unforeseen
circumstances, for some visits the timing could not be
completed for particular steps, (e.g. registration, blood tak-
ing). However, given the consistency of the timings that
had been obtained, the missed ones would likely not have
significantly altered the outcome. Our time and motion
protocol did not include assessing the time spent for un-
scheduled visits to the Centre for management of serious
adverse events and symptom control issues. Moreover,
during the treatment step the RA was only present for
medication changeovers, which may have resulted in an
underestimation of these work times. However, it is not
likely that additional costs associated with these limita-
tions would have significantly increased the impact of the
personnel costs as compared with the cost of the drugs.
This time and motion study also provided a detailed
description of the patient trajectory through our cancer
centre, giving a glimpse of the complexity of care of these
patients. The inefficiencies in patient flow, particularly
specific points with exaggerated wait times, correspond
directly with dissatisfaction consistently identified in two
patient satisfaction surveys conducted by the Jewish Gen-
eral Hospital’s Quality Program. Furthermore, simple ob-
servation of the use of the common space (corridors,
waiting areas) also aligns with the flow and waiting time
data documented in this study. For example, the lengthy
appointment booking time resulted in over-crowding of
the common space and undue stress on patients as they
waited to book their appointments. Process improve-
ments have now been implemented to facilitate appoint-
ment booking and decrease the time of that work step.
Given the relatively low proportion of personnel and fa-
cility usage cost in the total costs, improving efficiencies
in the patient flow are not likely to result in major cost
savings to the system. However, improving efficiency is of
the utmost importance in order to be well-equipped to
handle the increasing number of patients going through
the cancer trajectory, and is a process that has been
implemented at other cancer facilities [20-22].
Conclusions
In conclusion, by combining time and motion method-
ology with information from hospital databases we
determined that in the context of increasingly expensivetherapies, the relative contribution of personnel and
O&M costs to the overall cost is significantly smaller than
expected. The methodology in this study is a “bottom-up”
approach which only accounts for salaries attributed to
our study cases. However, a significant portion of work
time is typically spent on tasks not attributable to specific
cases and which we have not fully accounted for (with the
exception of O&M costs). We have also excluded phys-
ician salary costs in this analysis because they are not
hospital-based expenses in Quebec. In contrast, when ana-
lyzed for an entire health care system, salaries typically
comprise a significant portion of the costs, and in general
hospital care is provided with medications that are not as
expensive as those for cancer, with the number of person-
hours considerably higher. Thus in other countries with
different health care structures, personnel costs for phys-
ician and treatment visits for cancer care may account for
a greater proportion of the costs.
This study has also provided quantitative information
about patient and work flow which when used in conjunc-
tion with what has been observed in the clinic and what
patients have said, has helped guide the implementation of
process changes to increase efficiency. With the emerging
paradigm of 'personalized' medicine in which molecular
diagnostic testing increasingly guides treatment selection,
at times also requiring tumour biopsies for testing, there
will be new components in the cancer treatment teams.
Molecular pathologists, interventional radiologists and
their respective technical support may have to be added to
the already complex flow chart. Our approach can be used
as a template to examine the impact of these changes, as
health care managers decide on allocating these resources.
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